HEALTH LAW SECTION BLOG
The Official Blog of the New York State Bar Association Health Law Section
Entries from HEALTH LAW SECTION BLOG tagged with 'FDAAA'
FDAAA requirements update: drug safety, clinical trials database
A Draft Guidance for Industry about Medication Guides and REMS has been published for comment purposes (February 2011); the draft Guidance indicates that it is intended to address 2 topics pertaining to Medication Guides for drug and biological products-that...
Posted by Joan Shipman on April 6, 2011 3:05 PM
FDA's Quarterly Report: products and potential signals of serious risks/new safety information, AERS database.
Sept 5, 2008 FDA announced (1) that it has posted on its Web site its first quarterly report that lists certain drugs that are being evaluated for potential safety issues.(2) The drugs have been identified based on a review of...
Tags:
Posted by Joan Shipman on September 6, 2008 4:33 PM
In the spotlight: FDA key initiatives
Today's FDA webpage show key initatives in their 'Spotlight' focus. This provides a nice overview of what is happening here in recent history and links to the respective website that focuses on each initiative. Through specially targeted initiatives, FDA intensifies...
Posted by Joan Shipman on August 2, 2008 3:52 PM
FDA /CDERWarning Letters 2008-Bioresearch monitoring program
For purposes of thinking about trends, I found it interesting to take a look at the last 6 months of FDA/CDER Warning Letters resulting from inspections in regard to its Bioresearch Monitoring Program. The Warning Letters show recent and...
Posted by Joan Shipman on July 10, 2008 6:50 AM
Another context-the Pharmaceutical Business Review newsletter
For stargazers who visit Supra, here is a weekly publication I have found useful over time--it is grounded in business. The 'Business Digest' newsletter from the Pharmaceutical Business Review (1) published weekly, originates in the UK. With due respect to...
Posted by Joan Shipman on July 9, 2008 7:17 AM
Help for prescription drug/medical products safety: reactive dependence to proactive surveillance
May 22, 2008, HHS Secretary Mike Leavitt announced new FDA/CMS efforts that will complement each other to improve patient safety and the quality of medical care.(1) Read more about the big picture and how CBO sees the Federal government's Activities...
Tags:
Posted by Joan Shipman on May 23, 2008 7:32 AM
Preemption of state liability laws-several current perspectives
The U.S. House of Representatives, Committee on Oversight and Government Reform held a hearing titled, “Should FDA Drug and Medical Device Regulation Bar State Liability Claims?” on Wednesday, May 14, 2008.(1)Chairman Waxman's Opening Statement states in part: FDA approval of...
Tags:
Posted by Joan Shipman on May 20, 2008 11:26 AM
C. Brown on "Creating a positive culture for children"
From the State Bar News, NYSBA's Annual Meeting Edition (March/April 2008), an article by Cailin Brown on the Presidential Summit, am panel, leads the issue (1) ...Experts shared ideas on breaking the cycle for youth at risk, Cailin Brown reports,...
Posted by Joan Shipman on April 15, 2008 7:18 AM
FDAAA-a 5 yr safety plan
Just out: FDA's "Prescription Drug User Fee Act (PDUFA) IV Drug Safety Five-Year Plan" draft document dated March 2008.(1) FDA will use this plan to communicate strategies FDA will follow for using PDUFA IV drug safety resources; communicate our current...
Tags:
Posted by Joan Shipman on April 2, 2008 8:42 AM
FDAAA of 2007 and "REMS"
From CDER's email news of today: FDA provides Q&A on the Federal Register Notice on Drugs and Biological Products Deemed to Have A Risk Evaluation and Mitigation Strategy ("REMS"). (1) [re: 3/27/08 Federal Register Notice see (2)] FDA is: identifying...
Posted by Joan Shipman on March 27, 2008 1:52 PM
Genetic testing and the genomic era- perspectives for clinical practice
Zooming in to focus on particular sections of the FDA Amendments Act of 2007, I first took note of Section 1103 of the FDAAA, “improving genetic test safety and quality,” which requires that by July 2008 the Secretary’s Advisory Committee...
Posted by Joan Shipman on October 30, 2007 12:17 PM
Feed Subscription
If you use an RSS reader, you can subscribe to a feed of all future entries tagged 'FDAAA'. [What is this?]
Other Tags
Other tags used on this blog:
- aca (1)
- ACA (1)
- access (5)
- accreditation standards (1)
- ACLU (3)
- ACO (2)
- admission agreement (1)
- adult homes (1)
- advanced therapy medicinal products (1)
- adverse events (8)
- adverse selection (1)
- advisory opinion (1)
- AERs (4)
- aetna (4)
- affordable care act (2)
- age discrimination (1)
- AHRQ (5)
- AIDS (1)
- alternative dispute resolution (1)
- AMA (3)
- ambulance (1)
- ambulatory surgery center (1)
- animals in research (2)
- anti-kickback (4)
- antitrust (2)
- applied gene therapy (1)
- assisted living facilites (2)
- ATMPs (1)
- attorney general (13)
- audit (9)
- authentication (1)
- autopsy (1)
- AWP (3)
- bankruptcy (4)
- behavioral science (1)
- benefit mandates (3)
- benefits (1)
- Berger commission (10)
- bioethics (3)
- biologics (1)
- biomarkers (4)
- biomedical informatics (1)
- biomedical technology (3)
- biometrics (1)
- biosafety (1)
- biosimilars (1)
- blogging (9)
- blood donors (2)
- blood screening tests (1)
- body tissues (1)
- botanical preparation (1)
- BPA (2)
- BRCA (4)
- breast cancer (1)
- brokers (2)
- Brookhaven (1)
- budget (11)
- cancer (8)
- carbon pollution (1)
- care management (1)
- CBER (2)
- CBO (2)
- CDC (1)
- CDER (6)
- CDPHP (1)
- CDT (2)
- cell therapy (2)
- CERHR (1)
- charitable purpose (1)
- child health plus (2)
- children (3)
- China (4)
- chronic care coordination (1)
- chronic disease (1)
- church and state (1)
- cigna (1)
- CIPIH (2)
- Citizen Media Law Project (1)
- claims (1)
- CLE (1)
- climate change (1)
- clinical laboratories (2)
- clinical practice (1)
- clinical trials (21)
- cloning (2)
- CMS (2)
- co-branding (1)
- COBRA (1)
- COI (2)
- collaboration (1)
- collective bargaining (1)
- combinatorial chemistry (1)
- Commonwealth Fund (1)
- comparative effectiveness (2)
- comparative law (1)
- competitiveness (1)
- compliance plans (1)
- compound authorizations (1)
- compound libraries (1)
- comptroller (1)
- CON (2)
- concierge medicine (1)
- conflicts of interest (3)
- conscience clause (1)
- Constitutional Law (1)
- construction (2)
- consumer (4)
- consumer health information (4)
- continuum (1)
- conversion (3)
- COPS (1)
- corporate practice of medicine (1)
- counterfeits (1)
- court administration and law (1)
- criminal charges (12)
- cuomo (14)
- cyber vocabulary (1)
- daines (2)
- data breach (7)
- data protection (4)
- database (5)
- DDMAC (1)
- death rates (1)
- diagnosis (1)
- dietary science and health relations (1)
- digital doctor-rural (1)
- digital technology (1)
- Dipnote (1)
- DNA (2)
- doctors across new york (2)
- DOH (17)
- domestic partner (3)
- donor eligibility/ testing (1)
- dose registry (1)
- downtown (1)
- drug development (4)
- drug discovery (4)
- drug disposal (1)
- drug labels (4)
- drug prescribing practices (2)
- drug price reports (1)
- drug product life cycles (1)
- drug production capability (1)
- drug promotions violations (1)
- drug risk evaluation and mitigation strategy (3)
- drug safety (13)
- Drug Safety Communication (1)
- drug shortage (1)
- drug side effects (2)
- drug/biologics products safety (1)
- e-health (3)
- e-prescribing (2)
- EIN (1)
- electronic health records (12)
- electronic medical records (16)
- emergency care (4)
- emergency department (4)
- empire (2)
- employer identification numbers (1)
- EMR (5)
- EMS (1)
- energy (1)
- environmental health (3)
- EPA (1)
- EPHT (1)
- epidemiology (1)
- epigenetics (1)
- ERISA (2)
- errors (3)
- ESSCB (8)
- ESSCB Ethics Committee (2)
- ethics (12)
- ethnobotanical preparation (1)
- EU's EMA (2)
- Europe (2)
- European Food Safety Authority (1)
- evidence-based medicine (3)
- exclusion (2)
- executive compensation (1)
- exempt organizations (5)
- expansion (2)
- external appeal (1)
- extrapolation (1)
- false claims (6)
- family health care decisions act (3)
- family law (1)
- family planning (4)
- FDA (19)
- FDA employees/MAPP (1)
- FDA risk/benefit communications (1)
- FDA Science board (1)
- FDA's quality by design (1)
- FDA's weekly issues column (1)
- FDAAA (11)
- federal civil litigation (1)
- fertility (2)
- FHCDA (3)
- fines (7)
- First Amendment (1)
- food safety (4)
- food stamps (1)
- food/diet-related diseases (1)
- foundations (1)
- fraud (33)
- FTC (3)
- full disclosure/caveat emptor (1)
- fundraising (1)
- gamete donation (2)
- GAO (1)
- gene patents (2)
- gene therapy (4)
- generally accepted professional practices (1)
- generics (1)
- genetic information (6)
- genetic terms glossary (1)
- genetic testing (6)
- genomic medicine (5)
- genomic research (1)
- Geron's regenerative product pipeline (1)
- GFP (1)
- GHI/HIP (4)
- global academic-industry collaboration (1)
- global health (8)
- global publications benchmarking (1)
- globalized economy (1)
- GLP (1)
- GME (3)
- GMP (1)
- Good Clinical Practice (1)
- google (2)
- grant (6)
- H1N1 (6)
- HANYS (2)
- HCAHPS (1)
- HCFAC (1)
- HCLD (1)
- HCRA (2)
- HEAL grants (2)
- health care costs (6)
- health care disparities (2)
- health care interventions (1)
- health care reform (30)
- health home (1)
- Health Indicators Warehouse (1)
- health information (4)
- health information exchange (2)
- health insurance (11)
- health IT (2)
- health maintenance organizations (2)
- health product development (1)
- health research science (1)
- Health Research Science Board (1)
- health research services (2)
- health researchers (1)
- health sciences (1)
- health services research (2)
- healthcare and life sciences (1)
- HealthNet (1)
- healthnow (2)
- healthy ny (2)
- HESC (5)
- HHC (3)
- high throughput screening (1)
- HIPAA (26)
- HIPAA security (2)
- HITECH (1)
- HIV (2)
- HMOs (2)
- home health (5)
- hospital closings (25)
- hospital-patient relationship (1)
- hospitals (68)
- HSCI (1)
- human blood transfusions (1)
- human genome research (1)
- human rights (1)
- human subject protection (6)
- hypertension (1)
- I-STOP (1)
- Iceland (1)
- ICH (4)
- improved medical treatments (1)
- incident reporting (1)
- indictment (1)
- individual mandate (1)
- individualized medicine (1)
- infection (2)
- infection rates (2)
- infectious diseases (1)
- influenza (1)
- information security (9)
- information technology (18)
- informed consent (8)
- ingenix (6)
- innovation ecosystem (1)
- innovation for health outcomes (1)
- innovation life sciences (9)
- innovative medical technologies (1)
- Inspector general (3)
- insurance (7)
- insurance department (27)
- int'l FDA pilot programs (1)
- international DNA banks (1)
- international genetic laws (1)
- international harmonization (4)
- international harmonization: pharma regs (2)
- international health affairs (4)
- international health policy perspectives (7)
- international law (3)
- international pharma industry (1)
- international research standards (3)
- international scientific collaboration (5)
- Internet freedom (1)
- internet pharmacy (1)
- Internet speech (1)
- IOM (1)
- IP (1)
- iPS cells (2)
- iPS Center NIH (1)
- IRB (2)
- IRBs (1)
- IRS (5)
- iSCNT (1)
- ISSCR (2)
- Japan (2)
- joint commission (1)
- jonathan's law (1)
- judiciary (1)
- kendra's law (1)
- law blog ideas (8)
- law blog related (3)
- law blogging (3)
- laws (3)
- leapfrog group (2)
- legal practice (2)
- legal profession (2)
- legal resources (6)
- legal service business resources (1)
- legislation (8)
- life sciences (2)
- long term care (1)
- malpractice (5)
- mammograms (1)
- managed care (9)
- mandates (2)
- marijuana (2)
- Markle Connecting for Health (1)
- massachusetts (11)
- maternity (2)
- MDUFMA (2)
- mediation (1)
- medicaid (45)
- medicaid recovery audit program (1)
- medical diagnostics (1)
- medical error (1)
- medical home (3)
- medical imaging safety (1)
- medical information (1)
- medical liability reforms (1)
- medical malpractice (1)
- medical records (3)
- medical research (4)
- medical science (1)
- medically necessary drug products shortages (1)
- medicare (18)
- medicare advantage (1)
- Medication Guides (1)
- MediSys (1)
- meetings (2)
- Memorial Sloan-Kettering Cancer Center (2)
- mental health (10)
- mercy medical center (1)
- mergers (7)
- MFCU (2)
- michelle's law (1)
- microsoft (2)
- midwifery (1)
- molecular tests (1)
- montefiore (1)
- mount sinai (1)
- MSSNY (1)
- Myriad gene patents (1)
- nanobioscience (1)
- nanobusiness (1)
- nanotechnology (2)
- National Academies (1)
- National Health and Nutrition Survey (1)
- National Organ Transplantation Act (1)
- natural products in chemistry (1)
- natural/unatural in biology (1)
- NCI (1)
- NCRP (1)
- NCVIA (1)
- near-misses (1)
- never events (2)
- new therapies (1)
- New York medical research institutions (5)
- new york-presbyterian (2)
- newborn screening program (1)
- NHGRI (1)
- Nigeria (1)
- NIH Challenge Grants in Health and Science Research (1)
- NIH NCATS (1)
- NIH NHGRI (1)
- NIH OTT model agreements (1)
- NIH stem cell research (1)
- NIH's CTSA (1)
- NIH's Feedback blog (1)
- non-network care (1)
- nonclinical abuse liability (1)
- nonclinical safety/efficacy studies (1)
- not HIPAA (1)
- not-for-profit (7)
- notice (2)
- nursing (9)
- nursing homes (11)
- nutrition (3)
- NYeC (1)
- NYHISPC (1)
- NYLJ health article (11)
- NYS ESD (1)
- NYSBA blogs (1)
- NYSTEM (20)
- obesity (2)
- observation units (1)
- off-label drug uses (2)
- Office of Health Information Technology Transformation (1)
- OHITT (1)
- OHRP (2)
- OIG (8)
- OMH (1)
- OMIG (9)
- on-line collaboration (1)
- on-line medical records (1)
- on-line purchase of medicine (1)
- oocyte donation risks (1)
- OPASI (1)
- organ donation (2)
- organ donors (1)
- organ procurement (3)
- organ procurement organization (1)
- organ transplants-financial incentives (1)
- orphan drugs (1)
- orszag (1)
- out-of-network care (5)
- outpatient clinic (1)
- overpayment (4)
- oversight (2)
- overtime (1)
- P2P (1)
- P4P (1)
- pandemic (1)
- paradigm shift (T. Kuhn) (1)
- paradigms (1)
- Parkinson's disease (1)
- partnership for coverage (4)
- patent case pilot project (1)
- paterson (5)
- patient abuse (1)
- patient de-identified data (1)
- patient informed consent (1)
- patient medical imaging card (1)
- patient rights (2)
- patient safety (2)
- pay-for-performance (3)
- payment (2)
- payors (1)
- PCMH (3)
- PDUFA (2)
- pediatric population studies (1)
- pediatric research (1)
- peer review (7)
- personal health record (4)
- Personal Health Records (1)
- personalized medicine (7)
- personalized treatment (1)
- personally identifiable data (1)
- pharmacogenomics (1)
- pharmacy (6)
- PHI (1)
- PHR (2)
- PHRs (2)
- physician self-referral (7)
- physician shortage (4)
- placebos (1)
- pluripotent stem cells (1)
- policy (1)
- policy and law (1)
- policy ideas (4)
- policy settings (1)
- post approval study (1)
- postmarketing drug safety (1)
- postmarketing risk surveillance (1)
- poverty (2)
- PPACA (3)
- pre-market approval (1)
- preemption (1)
- preet bharara (1)
- presciption drugs (3)
- prescription (2)
- prescription drugs (14)
- Presidential Proclamation (1)
- pressure ulcer (1)
- preventive care (1)
- primary care (5)
- principles-based regulation (1)
- prior approval (1)
- privacy (27)
- prompt pay (3)
- property taxes (1)
- protein mapping (1)
- proton beam therapy (1)
- psychoactive drugs (1)
- public access (1)
- public health (3)
- public health council (2)
- public health surveillance (5)
- public private partnerships (9)
- public-private collaborative (1)
- PUBPAT (3)
- punitive damages (1)
- qarr (2)
- quality (15)
- quality assurance (1)
- R&D (2)
- rankings (13)
- rare diseases (1)
- ratios (1)
- rDNA research activity (1)
- readmissions (1)
- Reagan-Udall (1)
- records (1)
- recoupment (2)
- Redbook 2000 (1)
- redi-clinics (6)
- reform (14)
- regenerative medicine (7)
- regulations (8)
- regulatory processes (1)
- Regulatory Science Program NIH (1)
- reimbursement (5)
- religious employers (2)
- REMS (2)
- REMs (1)
- reporting (1)
- reports (1)
- reproduction toxicity studies (1)
- reproductive biology (1)
- research (2)
- research board governance (3)
- research consortium (1)
- research output (1)
- research resources (4)
- research subjects (1)
- results-oriented regulatory processes (1)
- retail clinics (7)
- reviews (2)
- RHIO (4)
- risk/benefit assessment research (1)
- rural physicians (1)
- Safe Use Initiative (1)
- SCHIP (1)
- science and statistics in law (1)
- science in law (13)
- science/philosophy (2)
- scientific integrity (6)
- SCNT (1)
- screening (4)
- security breach (2)
- serbaroli (16)
- shared savings (1)
- sheehan (2)
- simulated human browsing (1)
- single payer (2)
- spinal cord injury (1)
- spitzer (6)
- st. francis (1)
- st. vincent's (12)
- standardized measures (2)
- standards (6)
- standarized measures (1)
- stark (7)
- state initiatives (5)
- stem cells (35)
- subpoenas (1)
- subsidies (1)
- substance use disorder (1)
- Supreme Court (7)
- surcharges (1)
- swidler (1)
- synthetic biology (1)
- taxes (6)
- technology transfer (1)
- telemedicine (1)
- therapeutic cloning techniques (1)
- therapeutic development (1)
- tissue (2)
- tissue banking (1)
- torts (1)
- toxic chemical exposure (1)
- toxicology (1)
- transparency (15)
- twitter (1)
- UCR (2)
- UIDP (1)
- UK (2)
- uninsured (7)
- unions (6)
- unitedhealth (2)
- universal coverage (13)
- UNOS (1)
- upstate (3)
- US-China PPP (1)
- USITC global healthcare services biotech SMEs (1)
- usual and customary (6)
- vaccines (13)
- virus (1)
- wal-mart (1)
- Web of Science (1)
- web scraping (1)
- webcast (1)
- wellcare (1)
- wellness (2)
- wellpoint (1)
- whistleblower (1)
- World Health Assembly (1)
- young lawyers (1)